Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects

NCT00498914 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00498914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00498914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2007
Completion date
April 30, 2009
Enrollment
41 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell refractory, lymphoma, large-cell, diffuse